A New Paradigm for Engaging the War on Infectious Diseases
February 17, 2015, Noon
Durham Research Center Auditorium
From the 1950s through the 1970s, the success of antibiotics and vaccines in controlling or eradicating infectious diseases (ID) worldwide resulted in decreased emphasis on development of ID vaccines and therapeutics. The emergence in the past three decades of the potential for bioterrorist attacks as well as emerging diseases such as SARS, West Nile, avian flu, swine flu, Ebola, has reversed this trend and renewed interest in treatment and prophylaxis of ID. Unfortunately, since potential sales of therapeutics for bioterrorist pathogens are limited mainly to orders for government stockpiles (e.g., anthrax, smallpox, botulinum toxin), and the development cost is high, traditional large pharmaceutical companies have cut back R&D resources in this arena. To combat this investment shortfall, a new paradigm has emerged where public-private partnerships between the NIH, DOD, World Health Organization, private foundations, academia, and non-profits, are beginning to function like pharmaceutical companies to advance the development of promising ID drugs, even when there is little opportunity for profit. This talk will discuss the growing need for ID vaccines and therapeutics, present new models for discovering and developing them, and provide examples of public-private partnerships that have advanced therapeutics for specific infectious diseases.
Dr. Jon C. Mirsalis, Ph.D., D.A.B.T., is Managing Director of the Biosciences Division and Executive Director of Translational Development at SRI International in Menlo Park, CA. Dr. Mirsalis is an internationally recognized expert in the development of drugs for infectious diseases.
February 19-20, 2015
PCORI is hosting a free two-day interactive workshop to provide applicants with the tools and strategies to develop that winning application. This interactive workshop—led by expert staff—will offer an overview of PCORI:
- National Priorities for Research
- Funding announcements
- Application process
- Methodology Standards
- Patient and stakeholder engagement requirements
- Merit Review process
- Post-award administrative requirements
The workshop will provide opportunities to meet PCORI staff, ask questions, obtain resources, and network with other participants. On hand to offer additional insight will be our contract administrators, research program officers, engagement officers, and notable awardees who can provide both programmatic and administrative intelligence to help you apply for and manage a PCORI contract.
Sheraton North Houston at George Bush Intercontinental
15700 John F. Kennedy Boulevard
Houston, TX 77032
This Workshop is sponsored by the Patient-Centered Outcomes Research Institute. Read More.
For questions about:
Logistics and Registration, e-mail: firstname.lastname@example.org
Workshop Agenda and Speakers, e-mail: ContractsWorkshop@pcori.org
As of January 11th, 2015, the NIH salary cap will increase from $181,500 to $183,300.
Per the NIH, the terms “direct salary,” “salary,” and “institutional base salary” have the same meaning for the purposes of salary limitation and exclude fringe benefits and facilities and administrative (F&A) costs.
Per UNMC Institutional Base Salary policy #6102:
- Institutional base salary is capped at the current published NIH salary limitation level only for grant and contract proposals sponsored by the NIH or by those sponsors that utilize the NIH salary cap; for all other proposals, the total institutional base salary is used.
For more information: